По силимарину немало и клинических данных, напр. в лечении заболеваний печени:
Drugs. 2001; 61(14): 2035-63.
The use of silymarin in the treatment of liver diseases.
Saller R, Meier R, Brignoli R.
Abteilung Naturheilkunde, University Hospital Zurich, Switzerland.
...Analysis was performed on five trials with a total of 602 patients with liver cirrhosis. The evidence shows that, compared with placebo, silymarin produces a nonsignificant reduction of total mortality by -4.2% [odds ratio (OR) 0.75 (0.5 - 1.1)]; but that, on the other hand, the use of silymarin leads to a significant reduction in liver-related mortality of-7% [OR: 0.54 (0.3 - 0.9); p < 0.01]. An individual trial reported a reduction in the number of patients with encephalopathy of -8.7% (p = 0.06). In one study of patients with cirrhosis-related diabetes mellitus, the insulin requirement was reduced by -25% (p < 0.01). We conclude that available evidence suggests that silymarin may play a role in the therapy of (alcoholic) liver cirrhosis. Silymarin is has a good safety record and only rare case reports of gastrointestinal disturbances and allergic skin rashes have been published. This review does not aim to replace future prospective trials aiming to provide the 'final' evidence of the efficacy of silymarin.
Также получены неплохие предварительные данные о его положительном действии на течение HCV фиброза и теперь его тестируют в трайле PROFI-C (2000-2005, 320 пациентов) вместе с пег-интерфероном: лечение пегИФ +/- силимарин 840 мг у пациентов не ответивших на курсовое лечение пегИФ+рибавирин.
В отношении флавоноидов и др. антиоксидантных продуктов получаемых из какао, чая, вина и пр.
нравится следующее мнение:
Epidemiologic studies generally support the hypothesis that flavonoid consumption reduces cardiovascular risk. Short-term human and animal studies reveal numerous plausible mechanisms by which flavonoids may confer cardioprotective effects. These include primarily antioxidant effects, antithrombotic effects, improvement of endothelial function, and anti-inflammatory effects. Flavonoid content and bioactivity differ among different foods. Nutritional databases must be developed further to include the thousands of flavonoids present in plant-based food products, with information about their absorption, distribution, metabolism, and excretion. We also need information about the bioactivity of flavonoids under fresh, frozen, and cooked conditions. In the absence of randomized, controlled clinical trials to evaluate the ability of specific foods or flavonoids to reduce clinical cardiovascular events, there are no recommended daily intake goals for flavonoids. Nevertheless, given the accumulating evidence in favor of flavonoids, it seems prudent to consume a wide variety of flavonoid-rich foods and beverages.
Из Curr Atheroscler Rep. 2004 Jan; 6(1): 73-8.
Flavonoids for reduction of atherosclerotic risk.
Maron DJ.
Vanderbilt Page-Campbell Heart Institute, Vanderbilt University Medical Center, 2311 Pierce Avenue, Nashville, TN 37232-8802, USA. david.maron@vanderbilt.edu
